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Background: Osteosarcoma (OS) is the most common pediatric primary malignant bone tumor. As the prognosis
for patients following standard treatment did not improve for almost three decades, functional preclinical models
that closely reflect important clinical cancer characteristics are urgently needed to develop and evaluate new
treatment strategies. The objective of this study was to establish an orthotopic xenotransplanted mouse model
using patient-derived tumor tissue.
Methods: Fresh tumor tissue from an adolescent female patient with osteosarcoma after relapse was surgically
xenografted into the right tibia of 6 immunodeficient BALB/c Nu/Nu mice as well as cultured into medium. Tumor
growth was serially assessed by palpation and with magnetic resonance imaging (MRI). In parallel, a primary cell
line of the same tumor was established. Histology and high-resolution array-based comparative genomic
hybridization (aCGH) were used to investigate both phenotypic and genotypic characteristics of different passages
of human xenografts and the cell line compared to the tissue of origin.
Results: A primary OS cell line and a primary patient-derived orthotopic xenotranplanted mouse model were established.
MRI analyses and histopathology demonstrated an identical architecture in the primary tumor and in the xenografts.
Array-CGH analyses of the cell line and all xenografts showed highly comparable patterns of genomic progression. So far,
three further primary patient-derived orthotopic xenotranplanted mouse models could be established.
Conclusion: We report the first orthotopic OS mouse model generated by transplantation of tumor fragments directly
harvested from the patient. This model represents the morphologic and genomic identity of the primary tumor and
provides a preclinical platform to evaluate new treatment strategies in OS.
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Osteosarcoma (OS) is the most common malignant
pediatric bone tumor. Standard therapy comprises neo-
adjuvant chemotherapy, surgery and adjuvant chemo-
therapy with methotrexate, platin, alkylating agents and
anthracyclines. While patients with localized and oper-
able OS have a 5 year survival rate of approximately 60-
70%, outcome for patients with metastatic disease or
non-resectable tumors is poor [1]. Over the past 30 years,* Correspondence: c.blattmann@klinikum-stuttgart.de
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unless otherwise stated.survival rates did not improve. The development of new
therapeutic approaches is urgently needed. Therefore,
valid preclinical models reflecting human osteosarcomas
are crucially required to facilitate rapid and effective de-
velopment of novel therapies.
In principle, animal models can either be generated by
inducing a tumor in a model organism or by xenograft-
ing human cancer cells or tissue into immunodeficient
mice [2]. For the development of novel treatment strat-
egies, human tumor xenografts are currently the most
widely used models in a preclinical setting. They most
resemble the human tumor despite the restrictions due
to the immunodeficiency of the host organism. Genetic-
ally engineered mouse models (GEM) allow the study oftral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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these increasingly sophisticated models tissue specific mo-
lecular changes can be compared between individual can-
cers and tissues on the molecular level. Non-germline
genetically engineered models allow the analysis of the im-
pact of specific cancer genes without some of the limita-
tions inherent in traditional GEM models. As mechanisms
of transformation and oncogenesis differ between “mice
and men” the generation of clinically relevant models using
the mouse requires their humanization [3].
GEM have been instrumental in understanding the
molecular mechanisms involved in tumor initiation.
However, they have been less successful in replicating
advanced cancer. Moreover, a particular genetic alter-
ation frequently leads to different tumor types in human
and mouse and to lower metastatic rates in GEM than
in humans. These shortcomings limit the capacity of
current GEM models to predict clinical response to a
particular therapy. In contrast, orthotopic xenografts of
human tumors, or tumor cell lines, implanted in SCID
mice have high rate of reproducibility [4].
In OS, animal models are difficult to establish: osseous
tissue is difficult to handle mechanically and technically
challenging to be xenografted orthotopically. Previously,
subcutaneous xenografts and orthotopic OS mouse
models have been described using injection of cellFigure 1 Representative MRI and μCT images of mouse xenografts 4 to 8
tissue showing tibial tumor mass. A): μCT image of whole mouse body 8 w
MRI images of tumor growth from week 4 to week 8. Red arrows indicatesuspensions and commercially available human cell lines
[5-7]. Furthermore, there have been studies reporting
genetically engineered models as well as models that
employ tumor self-seeding following injection of tumor
cells into the blood circulation of nude mice [8-10].
However, the applicability of these models is limited be-
cause genetically manipulated tumor cells are used to es-
tablish such models.
Hence, our goal was to establish a novel preclinical
platform for rapid and effective development of new
treatment strategies. Our new model system allows the
generation of an orthotopic mouse model and a corre-
sponding OS cell line using patient derived primary OS
tissue.
MR imaging and histopathology, as well as array-CGH
analyses were used to compare progression and human
tumor. In addition, array-CGH analysis proved the gen-
etic stability of this model, which will be used for pre-
clinical developing of new treatment strategies in the
future.
Material and methods
Patients and tumor samples
Tumor tissue samples were obtained from a patient with
relapsed high-grade OS [11]. The study was approved by
the ethics committee of the Medical Faculty of theweeks after intratibial transplantation of patient-derived human OS
eeks after tumor inoculation. B) and C): μCT and T2 weighed (T2w)
tumor location.
Table 1 Patient characteristics of tissue used for generation of patient-derived orthotopic mouse model
Age & Gender 17 years, female
Primary disease diagnosed April 2008
- histopathology osteoblastic osteosarcoma
- Tumor location right femur epiphysis, no metastases
- Treatment according to EURAMOS 1 06/2008 – 11/2009, abortion of chemotherapy after the third postoperative cycle
by request of the patient and her parents
Extraarticular tumor resection of the right femur (09.09.2008) and implantation of a Mutars-Endoprothesis
(regression grade II according to Salzer-Kuntschik)
1. Relapse diagnosed 24 months after diagnose of primary disease
- histopathology - osteoblastic osteosarcoma
- Location - multifocal lesions in the right tibia, both lungs bilateral and the mediastinum
- treatment - no further treatment because of the significant reduced general conditions and by request of the patient
and her parents
Death of disease 8 weeks after diagnose of relapse
Family history - Oldest child of four children
- Youngest brother died because of an embryonal rhabdomyosarcoma in 2000
- Mother died because of a Mamma-Ca in 2006
- Father, one younger sister and one younger brother are healthy
- Diagnostic concerning familiar tumor predisposition syndrome was declined
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histopathological confirmation of the OS, the samples
are stored in NaCl 0.9% on ice. A portion of the sam-
ple was xenotransplanted immediately (fraction 1, see
below). The remaining part of the samples was split
into three further fractions (fraction 2 to 4) as follows:
fraction 2 was put into DMEM medium, 10% DMSO
(Dimethylsulfoxide), 20% FCS (fetal calf serum) and
1% NEAA (Non Essential Amino Acid) under sterile
conditions, was frozen stepwise to −80°C and then
transferred to liquid nitrogen. Fraction 3 was snap fro-
zen and stored in liquid nitrogen. The fourth fraction
was brought into cell culture in DMEM medium, 10%
FCS and 1% NEAA (Non Essential Amino Acid) under
sterile conditions and was cultured under standard
conditions.Figure 2 Representative MRI images of T1 weighed (T1w) and T2 weighed
post contrast tumor is not visible. C): Using T2w MRI imaging leasion size oEstablishment of xenografts
Fraction 1 of the human OS tissue was inserted into ten
week old athymic BALB/c Nu/Nu mice (Charles River,
Wilmington, Mass.) as follows:
Tumor samples were cut into 1 × 1 × 1 mm3 pieces.
The right tibia of 6 mice was opened in the central
(medial) part by drilling with a dental drill with a diam-
eter of 0.5 mm to insert one tumor fragment in contact
with the bone marrow. The anesthesia of mice was per-
formed with isoflurane inhalation (1,5-3,5 Vol% per liter
oxygen). After, the surgical wound was sutured. The
whole procedure took about 10 min per mouse. The per-
centage of success was 92%. The mice were maintained
under specific pathogen-free conditions, food and water
were supplied ad libitum. Housing and all procedures in-
volving the mice were performed according to the(T2w) performed at week 4. A) and B): In T1w MRI images pre and
f 48 μl (here equaling tumor size) can be discriminated (red arrow).
Figure 3 Establishment of patient-derived mouse model. Human OS tissue was transplanted into 6 mice with success rates of 50% in passage 1
(P1), 66% in passage 2 (P2) and 100% in passage 3 (P3). The number of days until tumor onset decreased from 40 (P1) to 30 (P2) to 20 days (P3).
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Center institutional animal care and use committee and
by the local responsible government department (Regier-
ungspräsidium Karlsruhe). Mice were observed daily for
tumor growth by palpation and inspection.
MicroCT scans were acquired using an Inveon PET/
SPECT/CT system (Siemens Medical Solutions, Knoxville,
TN, USA). A 12 minute and 30 seconds CT scan was per-
formed with parameter settings: 360 rotation steps, tube
voltage 50 kV, tube current 500 μA, binning 1 and exposure
time 400 ms. The pixel size was 0.0143 × 0.0143 ×
0.0143 mm. Image reconstruction was performed using the
conventional Inveon Research Workplace software 4.0. The
reconstruction filter was Shepp-Logan with a downsample
factor of 2. MRI was performed using a small animal MRIFigure 4 Establishment of the primary tumor cell line OS-RH-2011/5. The o
(P1*). After 26 days, cells were split and 3.75 × 106 cells were injected subc
three weeks, four of six mice developed a tumor mass, which was removed
passaged in culture (P2*), split after 20 days and again injected into the fla
which was removed and re-cultured (P3*)scanner (Bruker Icon, 1 Tesla, Ettlingen, Germany). Be-
cause sufficient contrast for tumor discrimination could
not be achieved using i.p. injection of Magnevist (Bayer
Schering Pharma) at a concentration of 0.5 mmol/ml for
contrast enhanced T1w mri, tumor growth was visualized
using T2w images (TE = 100 ms, TR = 2842 ms, FA = 180,
voxel size = 0.16x0,16x1 mm3, FOV 30x30 mm, matrix size
= 192x192, averages = 4). Lesion sizes were measured using
T2 weighed (T2w) images and were found to match with
tumor sizes obtained via μCT (Figure 1) and with weighed
resected tumor tissues (data not shown). Measurements
were performed by manual segmentation of the mass using
Bruker ParaVision software. Mice were immobilized during
the imaging procedures via Sevofluran inhalation narcosis
at a dosage of 4% in air.riginal tumor tissue was collected and directly cultivated into medium
utaneously into the left flank of six athymic BALB/c Nu/Nu mice. After
when reaching a volume of 1.500 mm3. Tumor cells were then
nk of six mice. After two weeks, all mice developed a tumor mass,
Figure 5 Microarray-based comparative genomic hybridization of the human tumor tissue, the three mice passages and the three cell line
passages. Primary orthotopic osteosarcoma xenografts and all cell line passages are genomically stable when compared to the tumor in the
patient. The mice tumors and the cell line passages showed similar and for osteosarcoma typical copy number aberrations.
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of 6 mice attaining 1500 mm3. Each tumor was then re-
moved and processed for the following analyses: (1)
histopathological examination (2) array-based compara-
tive genomic hybridization (aCGH) (see below), (3)
orthotopic re-transplantation into 6 further mice, (4) re-
cultivation in cell culture. One of the six tumors was cut
into 1 × 1 × 1 mm3 fragments and transferred twice into
6 mice per passage (designated as passage P1 to P3). In
the first passage (P1) three of six mice, in the second
passage (P2) four of six mice and in the third passage
(P3) six of six mice developed an orthotopic OS, which
were frozen as outlined above for further analysis.
Establishment of primary OS cell line
The original tumor tissue was collected and directly cul-
tivated into medium (P1*). After 26 days, cells were split
and 3.75 × 106 cells were injected subcutaneously into
the left flank of six athymic BALB/c Nu/Nu mice
(Charles River, Wilmington, Mass.). After three weeks,
four of six mice developed a tumor mass which was re-
moved when reaching a volume of 1500 mm3. Tumor
fragments were disaggregated and passaged again (P2*),
split after 20 days and injected into the flank of six fur-
ther mice. After two weeks, all mice developed a tumor
mass, which was removed, disaggregated and re-
passaged (P3*). Each resected xenograft was first disag-
gregated into a cell line and then cells were re-injected.
The cell line “passages” means sequentially passaged
cells subcutaneously through the mouse and not just in
culture. The third passage was used for further analysis.
Cells were tested and proved to be free of mycoplasma,
viral as well as cell contamination using in-house Multi-
plex cell Contamination testing (McCT) service [12].
Genetic stability of the cells was compared to the ori-
ginal human tumor sample at each passage by aCGH
(see below).Table 2 Frequent genetic aberrations in osteosarcoma
Gene locus (locus
name)
Human tissue OS-RH-
2011
Orthotopic mouse
P3
1p22.3 (BCL10) Gain / amplification Gain / amplification
3q13.31 (LSAMP) LOH / Del LOH / Del
3p26.1 (SUMF1) No variation No variation
6p21.1 (RUNX2) Gain / amplification Gain / amplification
7q31.33 (POT1) Gain / amplification Gain / amplification
8q24.21 (Myc) Gain / amplification Gain / amplification
13q14 (RB1) LOH / Del LOH / Del
17p13.1 (TP53) Gain / amplification Gain / amplification
17q25.1 (SLC25A19) Gain / amplification Gain / amplification
19q13 (GLTSCR1) Gain / amplification Gain / amplification
Loss of heterozygocity (LOH) was defined as log2 ratio per clone > − 0.25, AmplificaMicroarray-based comparative genomic hybridization
(a CGH)
Genomic DNA from fresh frozen tissue was isolated
using standard phenol-chloroform extraction. Genomic
DNA from cultured cells was isolated using the Blood
and Cell Culture Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. Selection of
genomic clones, isolation of BAC DNA, performance of
degenerate oligonucleotide primer-PCR, and preparation
of microarrays were performed as previously described
[13]. Labeling, hybridization, and washing procedure
were performed as reported previously [14]. Array- (or
matrix-) CGH was carried out as described, gains were
defined as copy number imbalances log2 ratio > 0,25 and
losses log2 ratio < −0,25 [15,16].
Histopathology
Histology was performed nine weeks after tumor im-
plantation into the mice. 3 μm thick whole tumor sec-
tions were cut from formalin-fixed, paraffin-embedded
(FFPE) tissue blocks of all tumors. Sections were stained
with hematoxylin-eosin (HE; Sigma-Aldrich, St Louis,
USA). Histological comparisons were performed by two
pathologists (AS, WW) using conventional HE-stainings
as well as PAS and Masson Trichrom staining.
Results
Establishment of a primary osteosarcoma orthotopic
mouse xenograft
Human OS tissue was collected from a 17 years old girl
with an OS relapse in the right tibia with pulmonary and
mediastinal metastases. Primary disease had been diag-
nosed two years previously with localized disease in the
right distal femur. She received neo-adjuvant chemother-
apy according to the EURAMOS 1 protocol [17]. The
tumor was then completely resected and showed a grade
2 histological response (according to Salzer-Kuntschik;tumor Subcutaneous mouse tumor
P3
Primary cell
cultureP3*
No variation Gain / amplification
No variation LOH / Del
LOH / Del No variation
No variation Gain / amplification
No variation Gain / amplification
Gain / amplification Gain / amplification
LOH / Del LOH / Del
No variation Gain / amplification
No variation Gain / amplification
No variation Gain / amplification
tion was defined as log2 ratio per clone > 0.25.
Figure 6 Representative histology of the tumors (Masson trichrom
staining). Note the intimate association of neoplastic disorganized,
fairly primitive trabeculae (bluish color) with the tumor cells (light red
cytoplasm), which either present as lace-like pattern A) or as broad
sheets B). The arrows indicate mitosis, (*) indicates neoplastic osteoid.
A): Relapsed primary osteosarcoma at the time of diagnosis (×20), B):
corresponding patient-derived xenograft of mouse passage P3 (×20).
As depicted here, the xenograft tumor closely resembles the relapsed
primary including the production of neoplastic bone. Note the
abundant mitotic tumor cells (arrows). C): Corresponding patient-
derived xenograft of mouse passage P3 at higher magnification
(framed detail from B; ×40).
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adjuvant chemotherapy. However, the protocol was dis-
continued by request of the patient and her family. The
patient’s mother died of breast cancer at an age of
43 years and the younger brother died of embryonal
rhabdomyosarcoma of the chest wall at an age of 12.
The patient and her family did not consent to molecular
diagnostic assessment to prove the presence of a familial
tumor predisposition syndrome (Table 1).
Following biopsy of the relapsed tumor at the right
tibia, tumor tissue was transplanted into the right tibia
of 6 athymic BALB/c Nu/Nu mice as described in the
methods section. After 40 days, 3/6 mice (Passage P1)
developed a visible and detectable tumor mass in the
MRI which was performed once a week (Figures 1 and
2). The tumors in the 3 mice were removed when the
volume reached 1.500 mm3. Tumor tissue of one mouse
was then re-transplanted immediately into the tibia of 6
further BALB/c Nu/Nu mice (Passage 2). In this passage
tumor growth was observed after 30 days in 4 of 6 mice.
When the tumor volume reached 1.500 mm3, the tu-
mors were removed. One of these tumors was re-
transplanted into 6 further mice (Passage 3), which all
engrafted after 20 days (Figure 3). At each step, only one
tumor was passaged.
The surrounding tissue of all tumors showed local in-
filtration into the soft tissue as well as the skin. However,
until day 60 after tumor implantation into the mice, we
could not find metastases anywhere.
Establishment of a primary OS cell line OS-RH-2011/5
Osteosarcoma tissue from our index patient was directly
cultivated (Passage P1*; see methods section). After
26 days, culture was split and 3.75 × 106 cells were
injected subcutaneously into the left flank of 6 mice.
After three weeks, four of six mice developed a tumor
mass, which was removed when reaching a volume of
1.500 mm3. Tumor cells were then passaged in culture
(P2*), split after 20 days and again injected into the flank
of six mice. After two weeks, all mice developed a tumor
mass, which was removed and re-cultured (P3*). Now,
the third culture is used for further experiments e.g. in-
vestigation of new treatment strategies (Figure 4). The
cells were monitored daily by microscopy. The cell
morphology remained stable and very similar to the cells
of origin (not shown).
Genetic and histopathological characterization of the
orthotopic patient-derived osteosarcoma xenograft and
the primary osteosarcoma cell line
We next analyzed the xenografts and the cell line pas-
sages by aCGH to detect genomic copy number varia-
tions (CNV) at a high resolution level. As expected for
osteosarcoma, this analysis revealed a multitude of CNV.
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played a very similar genomic pattern, which closely re-
sembled the genomic profile of the primary tumor tissue
(Figure 5). Furthermore, we identified identical aberra-
tions which are frequently observed in osteosarcoma
(e.g. amplification of Myc and LOH in RB1) [19]. For a
detailed overview see Table 2. These findings demon-
strate a striking stability of genomic copy number varia-
tions in both the orthotopic xenografts as well as in the
primary cell line. In addition, we compared the human
tissue, the tumor of orthotopic xenografts and subcuta-
neous tumors. Here, our results showed different genomic
patterns of the subcutaneous tumors compared to the hu-
man tumor and orthotopic tumors (Table 2). Gains of chro-
mosomes 1, 7, 17 and 19 are not present within the
subcutaneous OS model, in contrast an additional loss of
regions of chromosome 3 was derived. However, these ab-
errations are possibly not driver events on OS pathogenesis,
since these tumors arise with and without these alterations
in different anatomical compartments.
Additionally, we investigated the morphology of the
primary and our model system. To this end, mouse xe-
nografts were examined by two pathologists. Compared
to the clinical biopsies of the primary and relapsed
tumors, which were both diagnosed as conventional high
grade osteoblastic osteosarcoma, the xenografts dis-
played similar histological characteristics including mi-
totic figures and formation of neoplastic extracellular
bone matrix into which tumor cells were incorporated
(Figure 6).Discussion
There is a disappointing lack of progress in the outcome
of osteosarcoma patients over the last three decades des-
pite well designed and large international prospective
randomized clinical studies [20]. It is particularly notable
that osteosarcoma, although occurring in about 5% of
children and adolescents with cancer, is now the second
most common cause of death in this age group [21].
Therefore, development of new treatment strategies re-
quires systematic preclinical studies that can in turn be
translated into the clinic. Existing model systems of
osteosarcoma employ subcutaneous injections of immor-
talized established cell lines into the flank of mice. This
model is fast, cheap, reproducible and easy to handle in
experimental settings [7,22-28]. However, this model
does not sufficiently reflect the human situation.
In 1997, Crnalic et al. reported a novel spontaneous
metastasis model of human osteosarcoma developed
using orthotopic transplantation of intact tumor cells
into tibia of nude mice. Though, they used tumor tissue
obtained from the 32nd serial passage of subcutaneously
growing human osteosarcoma xenografts but did notperform any further genetic analysis to compare the
tumor of origin to the mouse tumor.
In contrast, the important innovation we report here is a
technique that enables orthotopic transplantation of human
osteosarcoma tissue directly into the tibia of immunodefi-
cient mice resulting in a reproducible and genetically repre-
sentative patient xenograft model. So far, our model was
established successfully using osteosarcoma tissue of three
further patients (data not shown). However, the method re-
quires specific technical skill and experience in animal
models. But despite the significantly higher technical com-
plexity and higher costs, such patient-derived orthotopic
xenografts models can better recapitulate the biology of the
human disease and thus facilitating the investigation of
novel treatment strategies in a setting that more closely re-
sembles the human primary tumor [29-33]. We are cur-
rently employing this novel tool to identify new
compounds for the systemic treatment of osteosarcoma
and for developing new strategies to achieve local control
by heavy ion radiotherapy [34,35].
Conclusions
In conclusion, we report the first orthotopic osteosar-
coma mouse xenograft model, established by transplant-
ation of tumor fragments directly harvested from the
patient. This model has been shown to closely reflect the
human disease on the level of morphology by MRI scan-
ning and histopathology as well as on the genomic level
as revealed by aCGH.
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